Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) will participate in analyst-led fireside chats at two upcoming healthcare conferences: the Jefferies London Healthcare Conference on Nov 18, 2025 at 1:30 PM GMT (8:30 AM ET) and the 37th Annual Piper Sandler Healthcare Conference on Dec 2, 2025 at 1:30 PM ET.

Live audio of both events will be available on the company’s Events page at investor.pacira.com, and webcasts will be replayable for two weeks after each event.

News Market Reaction – PCRX

+4.55%

1 alert

+4.55% News Effect

On the day this news was published, PCRX gained 4.55%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

• Jefferies London Healthcare Conference on Tuesday, November 18^th at 1:30PM GMT (8:30AM ET).
• 37^th Annual Piper Sandler Healthcare Conference on Tuesday, December 2^nd at 1:30PM ET.

Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

FAQ

When will Pacira (PCRX) present at the Jefferies London Healthcare Conference?

Pacira will present on Nov 18, 2025 at 1:30 PM GMT (8:30 AM ET).

What time is Pacira's (PCRX) fireside chat at the Piper Sandler Healthcare Conference?

The fireside chat is scheduled for Dec 2, 2025 at 1:30 PM ET.

How can investors listen to Pacira (PCRX) live webcasts for the November and December 2025 events?

Live audio is available on the Events page at investor.pacira.com.

Will Pacira (PCRX) provide replays of the conference webcasts and for how long?

Yes. Replays will be available for two weeks after each event on the investor events page.

Are the fireside chats with Pacira (PCRX) analyst-led or management presentations?

Both events are described as analyst-led fireside chats, indicating an interviewer format with company participants.

Where can I find the schedule and access links for Pacira (PCRX) conference appearances in Nov–Dec 2025?

Access the schedule and links on the company’s Events page at investor.pacira.com.